Clinical Trial Update: The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating laquinimod for relapsing-remitting multiple sclerosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2019-03-13